SOUTH SAN FRANCISCO
Somewhere in a Vera Therapeutics office today, employees are refreshing their inboxes every few minutes. Today is the day. July 7, 2026 is the FDA's official target action date — known in the industry as a PDUFA date — for a decision on atacicept, a twice-monthly-injectable drug that could become the newest weapon against a silent kidney disease most Americans have never heard of, despite it being one of the most common kidney disorders in the country.
The disease is called IgA nephropathy, sometimes known by its older name, Berger's disease. It is caused by a buildup of a specific antibody — immunoglobulin A, or IgA — that clumps together and lodges in the tiny filtering units of the kidneys. Over months and years, those clumps trigger inflammation and scarring that permanently damages the kidney's ability to filter blood. For a shockingly large number of patients, the disease develops with no obvious symptoms for years, sometimes decades, until either a routine urine test turns up blood or protein, or the kidneys have already sustained serious, sometimes irreversible damage.
The Disease That Sneaks Up on You
Doctors describe IgA nephropathy as a slow, silent thief. Early on, patients may notice nothing at all. As it progresses, warning signs can include pink or cola-colored urine from blood leaking into it, foamy urine from protein spilling out, and swelling in the legs, ankles, or feet as the body struggles to manage fluid. By the time kidney failure sets in, patients face nausea, exhaustion, headaches, and disrupted sleep — and their options narrow to dialysis or a kidney transplant.
The numbers are sobering: roughly 1 in 5 people diagnosed with IgA nephropathy will develop kidney failure within 10 years, according to kidney health researchers, making it one of the leading causes of kidney failure that isn't tied to diabetes or high blood pressure. Unlike those two better-known kidney disease drivers, IgA nephropathy typically strikes younger and middle-aged adults, robbing them of decades of healthy kidney function at a stage of life when a transplant or years of dialysis can be devastating to careers, families, and finances.
The Science Behind Atacicept
Atacicept works by targeting the disease at what researchers believe is its actual source, rather than just managing the downstream kidney damage. The drug is what's known as a fusion protein, engineered to bind to and neutralize two specific molecules in the immune system: BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). Both of those molecules fuel the survival and activity of B-cells, the immune cells responsible for churning out the harmful IgA antibodies that clog up the kidneys in the first place. By choking off both BAFF and APRIL simultaneously, atacicept aims to shut down the antibody-manufacturing process at its root, rather than simply treating the inflammation and scarring after the damage is already done.
If approved, atacicept would become the first dual BAFF/APRIL inhibitor available for IgA nephropathy anywhere in the world — a genuinely novel mechanism, not just a new brand name for an old approach. “Atacicept offers a distinct approach through dual targeting of BAFF and APRIL, which we believe could advance the standard of care in IgAN, if approved,” said Marshall Fordyce, M.D., founder and CEO of Vera Therapeutics.
The Trial Data That Got Everyone's Attention
The clinical results behind today's FDA decision come from a Phase 3 trial called ORIGIN 3, and they were significant enough to earn a rare honor: a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology's Kidney Week 2025, with simultaneous publication in the New England Journal of Medicine — one of the most prestigious placements in all of medical research.
The headline numbers: in a prespecified interim analysis, patients taking atacicept saw a 46% reduction in proteinuria — the medical term for excess protein leaking into urine, a key marker of kidney damage — from their baseline levels. Compared against a placebo group, that translated to a statistically significant 42% reduction, with a p-value below 0.0001, a threshold that leaves little room for the results being a statistical fluke. The trial hit its primary endpoint at week 36, a relatively fast timeline for a chronic kidney condition that typically takes years to show measurable improvement.
Beyond the topline efficacy numbers, atacicept has already picked up two of the FDA's most coveted regulatory designations on its way to today's decision: Breakthrough Therapy Designation, reflecting the agency's own assessment that the drug may show substantial improvement over existing treatments, and Priority Review, which compresses the standard review timeline in recognition of the drug's potential significance for patients with few other options.
What Happens if It's Approved Today
Under the FDA's Accelerated Approval Program — the same regulatory pathway that has ushered in faster approvals for certain cancer and rare disease drugs — atacicept could become available to prescribe based on the proteinuria reduction data alone, even before longer-term kidney function data is fully finalized. Vera Therapeutics has said it is on track for a U.S. commercial launch in 2026 pending approval, and the company has structured the drug for patient convenience: a once-weekly subcutaneous injection delivered via an autoinjector, designed so patients can administer it themselves at home rather than requiring infusion-center visits.
But today's decision, whichever way it goes, isn't necessarily the end of the story for atacicept. Vera Therapeutics has already announced it aligned with the FDA on a revised, earlier analysis of a separate kidney-function measurement called eGFR (estimated glomerular filtration rate) — essentially, a direct measure of how well the kidneys are actually filtering blood, as opposed to the indirect proteinuria marker used in today's accelerated approval decision. That eGFR data is expected in the third quarter of 2026, and if it's supportive, Vera plans to file for full, non-accelerated approval by the fourth quarter of 2026, with a possible decision in 2027. In other words: today's ruling determines whether atacicept reaches patients on an accelerated timeline this year, while the ultimate, full-approval verdict is still roughly a year away.
Fordyce has framed the moment as a culmination of years of execution. “The team at Vera Therapeutics is focused on execution as we advance atacicept toward potential FDA accelerated approval in IgAN,” he said in the company's most recent quarterly update, adding that the company has spent recent months building out “sales, marketing, market access, compliance, and commercial operations, to support a successful U.S. launch, pending regulatory approval.”
The Bigger Picture for Patients With No Great Options
Part of what makes today's decision so closely watched inside the kidney-disease community is how few effective, disease-modifying treatment options currently exist for IgA nephropathy. For years, standard management has largely consisted of blood-pressure control medications and, more recently, a handful of newer drugs that reduce inflammation or block different parts of the immune cascade — but none that specifically shut down both BAFF and APRIL together, the way atacicept is designed to. For a disease that can take away decades of healthy kidney function from people who are otherwise in the prime of their lives, a treatment that intervenes earlier and more precisely at the antibody-production stage represents a meaningfully different strategy than symptom management alone.
Vera Therapeutics isn't stopping at IgA nephropathy either. The company has said it believes BAFF/APRIL dual inhibition “has the potential to transform the treatment landscape for other autoimmune diseases” beyond kidney disease, and has already begun expanding atacicept's development program into additional autoimmune kidney conditions through a program called PIONEER, which aims to give a significantly larger number of patients access to the drug.
What This Means for You
If you or a family member has ever had a routine urine test flag blood or protein without a clear explanation, IgA nephropathy is worth asking your doctor about directly — it is frequently under-recognized because it causes so few symptoms in its early stages, and early detection meaningfully changes long-term outcomes regardless of which treatments are available. Anyone already diagnosed with IgA nephropathy should watch for news out of the FDA in the coming days, and discuss with their nephrologist whether atacicept, if approved, could be an appropriate addition to their care plan once it becomes commercially available. As with any newly approved biologic drug, cost and insurance coverage will likely be significant early hurdles, and patients should expect a period of adjustment as healthcare systems establish access pathways.
More broadly, today's decision is being watched closely across the biotech and nephrology worlds as a test case for how the FDA balances faster, biomarker-based accelerated approvals against the slower, gold-standard confirmation of real kidney-function benefit. However the ruling lands, it will shape expectations for a wave of similar B-cell-targeting drugs currently working their way through trials for other kidney and autoimmune conditions.
Conclusion
By the time most people finish their evening news tonight, the FDA's verdict on atacicept should be public. For the patients living with a disease that often gives no warning until real damage is already done, today's decision is about far more than a stock ticker or a corporate press release — it's about whether a new kind of shot, aimed squarely at the root cause of their illness, finally reaches doctors' offices this year.
